Windlas Biotech Files FY26 Annual Report
Windlas Biotech Ltd has submitted its Annual Report for the financial year ended March 31, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, also available on the company's website, includes forward-looking statements regarding anticipated results and prospects. Key investor information such as market capitalization of ₹15,550.01 Millions as of March 31, 2026, CIN, BSE/NSE codes, and a recommended dividend of ₹6.30/- are provided. The 25th Annual General Meeting is scheduled for July 23, 2026, to be held via VC/OAVM. The report details the company's corporate overview, financial performance, research expertise, manufacturing capabilities, future roadmap, business verticals, stakeholder engagement, human resources, and social contributions.
Key Highlights
- Annual Report for FY26 filed with SEBI and uploaded on company website.
- Market capitalization stood at ₹15,550.01 Millions as of March 31, 2026.
- Dividend recommended at ₹6.30/- per share.
- 25th AGM scheduled for July 23, 2026, via VC/OAVM.
- Report contains forward-looking statements and details company's performance.
Price Impact
More from WINDLAS*